531 related articles for article (PubMed ID: 19285067)
1. In vitro and in vivo pharmacological characterization of PF-01354082, a novel partial agonist selective for the 5-HT(4) receptor.
Mikami T; Komada T; Sugimoto H; Suzuki K; Ohmi T; Kimura N; Naganeo R; Nakata E; Nakatani K; Toga T; Eda H; Sakakibara M
Eur J Pharmacol; 2009 May; 609(1-3):5-12. PubMed ID: 19285067
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization and determination of pharmacokinetic and pharmacodynamic relationship of PF-00885706, a novel partial agonist selective for the 5-HT(4) receptor.
Komada T; Matsuura T; Mikami T; Suzuki K; Sugimoto H; Kimura N; Ohmi T; Toga T; Nakai Y; Eda H; Sakakibara M
Pharmacol Res; 2009 Oct; 60(4):237-46. PubMed ID: 19717010
[TBL] [Abstract][Full Text] [Related]
3. 5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-alpha]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroprokinetic effect in conscious dogs.
Mikami T; Ochi Y; Suzuki K; Saito T; Sugie Y; Sakakibara M
J Pharmacol Exp Ther; 2008 Apr; 325(1):190-9. PubMed ID: 18198343
[TBL] [Abstract][Full Text] [Related]
4. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
Tapia I; Alonso-Cires L; López-Tudanca PL; Mosquera R; Labeaga L; Innerárity A; Orjales A
J Med Chem; 1999 Jul; 42(15):2870-80. PubMed ID: 10425096
[TBL] [Abstract][Full Text] [Related]
5. WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity.
Dunlop J; Sabb AL; Mazandarani H; Zhang J; Kalgaonker S; Shukhina E; Sukoff S; Vogel RL; Stack G; Schechter L; Harrison BL; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2005 May; 313(2):862-9. PubMed ID: 15705738
[TBL] [Abstract][Full Text] [Related]
6. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties.
Moser PC; Bergis OE; Jegham S; Lochead A; Duconseille E; Terranova JP; Caille D; Berque-Bestel I; Lezoualc'h F; Fischmeister R; Dumuis A; Bockaert J; George P; Soubrié P; Scatton B
J Pharmacol Exp Ther; 2002 Aug; 302(2):731-41. PubMed ID: 12130738
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
8. Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.
Becker DP; Flynn DL; Moormann AE; Nosal R; Villamil CI; Loeffler R; Gullikson GW; Moummi C; Yang DC
J Med Chem; 2006 Feb; 49(3):1125-39. PubMed ID: 16451077
[TBL] [Abstract][Full Text] [Related]
9. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
[TBL] [Abstract][Full Text] [Related]
10. 5-HT4 receptor agonists: similar but not the same.
De Maeyer JH; Lefebvre RA; Schuurkes JA
Neurogastroenterol Motil; 2008 Feb; 20(2):99-112. PubMed ID: 18199093
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of DA-6886, a novel 5-HT4 receptor agonist to accelerate colonic motor activity in mice.
Lee MJ; Cho KH; Park HM; Sung HJ; Choi S; Im W
Eur J Pharmacol; 2014 Jul; 735():115-22. PubMed ID: 24769304
[TBL] [Abstract][Full Text] [Related]
12. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro.
Mine Y; Yoshikawa T; Oku S; Nagai R; Yoshida N; Hosoki K
J Pharmacol Exp Ther; 1997 Dec; 283(3):1000-8. PubMed ID: 9399969
[TBL] [Abstract][Full Text] [Related]
13. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo.
Beattie DT; Smith JA; Marquess D; Vickery RG; Armstrong SR; Pulido-Rios T; McCullough JL; Sandlund C; Richardson C; Mai N; Humphrey PP
Br J Pharmacol; 2004 Nov; 143(5):549-60. PubMed ID: 15466450
[TBL] [Abstract][Full Text] [Related]
14. SC-49518 enhances gastric emptying of solid and liquid meals and stimulates gastrointestinal motility in dogs by a 5-hydroxytryptamine4 receptor mechanism.
Gullikson GW; Virina MA; Loeffler RF; Yang DC; Goldstin B; Wang SX; Moummi C; Flynn DL; Zabrowski DL
J Pharmacol Exp Ther; 1993 Jan; 264(1):240-8. PubMed ID: 8380862
[TBL] [Abstract][Full Text] [Related]
15. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.
Heinrich JN; Brennan J; Lai MH; Sullivan K; Hornby G; Popiolek M; Jiang LX; Pausch MH; Stack G; Marquis KL; Andree TH
Eur J Pharmacol; 2006 Dec; 552(1-3):36-45. PubMed ID: 17056032
[TBL] [Abstract][Full Text] [Related]
16. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle.
Prins NH; Akkermans LM; Lefebvre RA; Schuurkes JA
Br J Pharmacol; 2001 Nov; 134(6):1351-9. PubMed ID: 11704657
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist.
Picard M; Morisset S; Cloix JF; Bizot JC; Guerin M; Beneteau V; Guillaumet G; Hevor TK
Neuroscience; 2010 Sep; 169(3):1337-46. PubMed ID: 20580787
[TBL] [Abstract][Full Text] [Related]
19. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.
Briejer MR; Bosmans JP; Van Daele P; Jurzak M; Heylen L; Leysen JE; Prins NH; Schuurkes JA
Eur J Pharmacol; 2001 Jun; 423(1):71-83. PubMed ID: 11438309
[TBL] [Abstract][Full Text] [Related]
20. Characterization of U-92016A as a selective, orally active, high intrinsic activity 5-hydroxytryptamine1A agonist.
McCall RB; Romero AG; Bienkowski MJ; Harris DW; McGuire JC; Piercey MF; Shuck ME; Smith MW; Svensson KA; Schreur PJ
J Pharmacol Exp Ther; 1994 Nov; 271(2):875-83. PubMed ID: 7965808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
